Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation

Zhifei Shao, Arpita S. Bharadwaj, Halvor S. McGee, Toluwalope O. Makinde, Devendra K. Agrawal

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Dendritic cell (DC) subsets display different functional roles in regulating immune responses and lead to various outcomes, including TH1 versus TH2 or regulatory versus immunologic responses. Administration of Fms-like tyrosine kinase 3 (Flt3) ligand prevents and reverses allergic airway inflammation and airway hyperresponsiveness in a mouse model. However, the underlying mechanisms are unclear. Objective: We characterized and examined the role of lung DC subsets in the therapeutic effect of Flt3 ligand. Methods: DCs were isolated from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged mice treated with recombinant human Flt3 ligand. Two populations of CD11c+ cells labeled with fluorochrome-conjugated antibodies were sorted. The ability of the purified cells to stimulate T-cell proliferation and cytokine secretion patterns by different DC subsets was examined. Also, DCs were adoptively transferred in mice to examine their effect on pulmonary function. Results: Two DC populations, CD11chighCD11blow and CD11clowCD11bhigh, were identified in the lungs of naive and OVA-sensitized and OVA-challenged mice with and without treatment with Flt3 ligand. The expression levels of CD8α, B220, CD19, F4/80, MHC II, CCR7, CD40, programmed death ligand 1, programmed death ligand 2, CD80, and CD86 were distinctly different between the 2 DC populations, which supports the notion that CD11chighCD11blow and CD11clowCD11bhigh DCs potentially have regulatory and immunogenic properties, respectively. Administration of Flt3 ligand increased the DCs with regulatory potential in the lungs of antigen-sensitized mice, and CD11chighCD11blow DCs acquired a maximum degree of regulatory capacity after Flt3 ligand treatment. Conclusion: These data suggest that Flt3 ligand reverses airway hyperresponsiveness by regulating the function of lung DCs in a mouse model of allergic airway inflammation.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
Volume123
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Dendritic Cells
Inflammation
Ovalbumin
Lung
Population
Ligands
Therapeutic Uses
flt3 ligand protein
Fluorescent Dyes
Cell Proliferation
Cytokines
T-Lymphocytes
Antigens
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation. / Shao, Zhifei; Bharadwaj, Arpita S.; McGee, Halvor S.; Makinde, Toluwalope O.; Agrawal, Devendra K.

In: Journal of Allergy and Clinical Immunology, Vol. 123, No. 4, 04.2009.

Research output: Contribution to journalArticle

@article{5c8869ab9f2746609e7d6a9d17675b3f,
title = "Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation",
abstract = "Background: Dendritic cell (DC) subsets display different functional roles in regulating immune responses and lead to various outcomes, including TH1 versus TH2 or regulatory versus immunologic responses. Administration of Fms-like tyrosine kinase 3 (Flt3) ligand prevents and reverses allergic airway inflammation and airway hyperresponsiveness in a mouse model. However, the underlying mechanisms are unclear. Objective: We characterized and examined the role of lung DC subsets in the therapeutic effect of Flt3 ligand. Methods: DCs were isolated from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged mice treated with recombinant human Flt3 ligand. Two populations of CD11c+ cells labeled with fluorochrome-conjugated antibodies were sorted. The ability of the purified cells to stimulate T-cell proliferation and cytokine secretion patterns by different DC subsets was examined. Also, DCs were adoptively transferred in mice to examine their effect on pulmonary function. Results: Two DC populations, CD11chighCD11blow and CD11clowCD11bhigh, were identified in the lungs of naive and OVA-sensitized and OVA-challenged mice with and without treatment with Flt3 ligand. The expression levels of CD8α, B220, CD19, F4/80, MHC II, CCR7, CD40, programmed death ligand 1, programmed death ligand 2, CD80, and CD86 were distinctly different between the 2 DC populations, which supports the notion that CD11chighCD11blow and CD11clowCD11bhigh DCs potentially have regulatory and immunogenic properties, respectively. Administration of Flt3 ligand increased the DCs with regulatory potential in the lungs of antigen-sensitized mice, and CD11chighCD11blow DCs acquired a maximum degree of regulatory capacity after Flt3 ligand treatment. Conclusion: These data suggest that Flt3 ligand reverses airway hyperresponsiveness by regulating the function of lung DCs in a mouse model of allergic airway inflammation.",
author = "Zhifei Shao and Bharadwaj, {Arpita S.} and McGee, {Halvor S.} and Makinde, {Toluwalope O.} and Agrawal, {Devendra K.}",
year = "2009",
month = "4",
doi = "10.1016/j.jaci.2009.01.052",
language = "English",
volume = "123",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation

AU - Shao, Zhifei

AU - Bharadwaj, Arpita S.

AU - McGee, Halvor S.

AU - Makinde, Toluwalope O.

AU - Agrawal, Devendra K.

PY - 2009/4

Y1 - 2009/4

N2 - Background: Dendritic cell (DC) subsets display different functional roles in regulating immune responses and lead to various outcomes, including TH1 versus TH2 or regulatory versus immunologic responses. Administration of Fms-like tyrosine kinase 3 (Flt3) ligand prevents and reverses allergic airway inflammation and airway hyperresponsiveness in a mouse model. However, the underlying mechanisms are unclear. Objective: We characterized and examined the role of lung DC subsets in the therapeutic effect of Flt3 ligand. Methods: DCs were isolated from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged mice treated with recombinant human Flt3 ligand. Two populations of CD11c+ cells labeled with fluorochrome-conjugated antibodies were sorted. The ability of the purified cells to stimulate T-cell proliferation and cytokine secretion patterns by different DC subsets was examined. Also, DCs were adoptively transferred in mice to examine their effect on pulmonary function. Results: Two DC populations, CD11chighCD11blow and CD11clowCD11bhigh, were identified in the lungs of naive and OVA-sensitized and OVA-challenged mice with and without treatment with Flt3 ligand. The expression levels of CD8α, B220, CD19, F4/80, MHC II, CCR7, CD40, programmed death ligand 1, programmed death ligand 2, CD80, and CD86 were distinctly different between the 2 DC populations, which supports the notion that CD11chighCD11blow and CD11clowCD11bhigh DCs potentially have regulatory and immunogenic properties, respectively. Administration of Flt3 ligand increased the DCs with regulatory potential in the lungs of antigen-sensitized mice, and CD11chighCD11blow DCs acquired a maximum degree of regulatory capacity after Flt3 ligand treatment. Conclusion: These data suggest that Flt3 ligand reverses airway hyperresponsiveness by regulating the function of lung DCs in a mouse model of allergic airway inflammation.

AB - Background: Dendritic cell (DC) subsets display different functional roles in regulating immune responses and lead to various outcomes, including TH1 versus TH2 or regulatory versus immunologic responses. Administration of Fms-like tyrosine kinase 3 (Flt3) ligand prevents and reverses allergic airway inflammation and airway hyperresponsiveness in a mouse model. However, the underlying mechanisms are unclear. Objective: We characterized and examined the role of lung DC subsets in the therapeutic effect of Flt3 ligand. Methods: DCs were isolated from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged mice treated with recombinant human Flt3 ligand. Two populations of CD11c+ cells labeled with fluorochrome-conjugated antibodies were sorted. The ability of the purified cells to stimulate T-cell proliferation and cytokine secretion patterns by different DC subsets was examined. Also, DCs were adoptively transferred in mice to examine their effect on pulmonary function. Results: Two DC populations, CD11chighCD11blow and CD11clowCD11bhigh, were identified in the lungs of naive and OVA-sensitized and OVA-challenged mice with and without treatment with Flt3 ligand. The expression levels of CD8α, B220, CD19, F4/80, MHC II, CCR7, CD40, programmed death ligand 1, programmed death ligand 2, CD80, and CD86 were distinctly different between the 2 DC populations, which supports the notion that CD11chighCD11blow and CD11clowCD11bhigh DCs potentially have regulatory and immunogenic properties, respectively. Administration of Flt3 ligand increased the DCs with regulatory potential in the lungs of antigen-sensitized mice, and CD11chighCD11blow DCs acquired a maximum degree of regulatory capacity after Flt3 ligand treatment. Conclusion: These data suggest that Flt3 ligand reverses airway hyperresponsiveness by regulating the function of lung DCs in a mouse model of allergic airway inflammation.

UR - http://www.scopus.com/inward/record.url?scp=63449130201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449130201&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2009.01.052

DO - 10.1016/j.jaci.2009.01.052

M3 - Article

VL - 123

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -